A Study to Evaluate the the Pharmacokinetic Interactions and Safety of MK-8742 (Elbasvir) Co-administered with Either Tenofovir-disoproxil-fumarate, Raltegravir, or Efavirenz in Healthy Subjects

Trial Profile

A Study to Evaluate the the Pharmacokinetic Interactions and Safety of MK-8742 (Elbasvir) Co-administered with Either Tenofovir-disoproxil-fumarate, Raltegravir, or Efavirenz in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2015

At a glance

  • Drugs Efavirenz (Primary) ; Elbasvir (Primary) ; Raltegravir (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B; Hepatitis C; HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 19 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top